| 1 |
NCT00776412 |
Recruiting |
Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Obtain blood samples for further investigation into the correlation between markers of coagulation, including D-dimer, and markers of platelet function, inflammation, endothelial cell function, and clinical parameters in HIV-infected adults.
|
375 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT00776412 |
090013
09-I-0013 |
|
October 17, 2008 |
|
|
October 21, 2008 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 2 |
NCT00687882 |
Recruiting |
Evaluation of the Duration of Therapy for Thrombosis in Children |
|
- Other: Shortened duration (6 weeks) of anticoagulant therapy
- Other: Conventional duration (3 months) of anticoagulant therapy
- Other: No Intervention
|
Interventional |
Phase 3 |
- Johns Hopkins All Children's Hospital
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Bivariate endpoint.
- Prevalence/severity of post-thrombotic syndrome.
|
815 |
All |
up to 20 Years (Child, Adult) |
NCT00687882 |
IRB00063928
1U01HL130048-01A1 |
Kids-DOTT |
March 2008 |
June 30, 2021 |
June 30, 2022 |
June 2, 2008 |
March 20, 2018 |
|
- University of Alabama Birmingham
Birmingham, Alabama, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - Children's Hospital Los Angeles
Los Angeles, California, United States - (and 56 more...)
|
| 3 |
NCT00230165 |
Recruiting |
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders. |
|
|
Observational |
|
- Rockefeller University
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
|
60 |
All |
Child, Adult, Senior |
NCT00230165 |
BCO-0417/0726
5R01HL019278-39 |
|
September 2005 |
June 2019 |
June 2019 |
September 30, 2005 |
September 8, 2017 |
|
- Rockefeller University Hospital
New York, New York, United States
|
| 4 |
NCT03080883 |
Recruiting |
Apixaban in Preventing Secondary Cancer Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy |
- Deep Vein Thrombosis
- Malignant Neoplasm
- Metastatic Malignant Neoplasm
- Pulmonary Embolism
|
|
Interventional |
Phase 3 |
- Academic and Community Cancer Research United
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Proportion of patients who experience at least one bleeding event
- Proportion of patients who experienced at least one bleeding event
- Venous thromboembolism recurrence
|
370 |
All |
18 Years and older (Adult, Senior) |
NCT03080883 |
ACCRU-SC-1601
NCI-2017-00325
P30CA015083 |
|
July 14, 2017 |
May 1, 2020 |
May 1, 2020 |
March 15, 2017 |
March 16, 2018 |
|
- NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, United States - Carle Cancer Center
Urbana, Illinois, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - (and 9 more...)
|
| 5 |
NCT02148029 |
Recruiting |
Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome |
- Acute Deep Vein Thrombosis
|
- Other: Exercise
- Other: Control
|
Interventional |
Not Applicable |
- VA Office of Research and Development
- University of Maryland
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Post Thrombotic Syndrome (Villalta Score)
- Quality of LIfe (SF 36, VEINS-QOL)
|
260 |
All |
18 Years and older (Adult, Senior) |
NCT02148029 |
F0995-R |
EFFORT2 |
July 1, 2014 |
December 31, 2018 |
December 31, 2018 |
May 28, 2014 |
November 17, 2017 |
|
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
Baltimore, Maryland, United States
|
| 6 |
NCT02108041 |
Recruiting |
Personalized Medicine Decision-Making in a Virtual Clinical Setting |
- Deep Vein Thrombosis
- Blood Clots
|
|
Observational |
|
- National Human Genome Research Institute (NHGRI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- To examine how physicians make treatment plan decisions for patients with DVT.
|
260 |
All |
21 Years and older (Adult, Senior) |
NCT02108041 |
999914075
14-HG-N075 |
|
April 5, 2014 |
July 31, 2018 |
July 31, 2018 |
April 9, 2014 |
December 28, 2017 |
|
- Johns Hopkins School of Medicine
Baltimore, Maryland, United States - Harvard School of Public Health
Boston, Massachusetts, United States - Michigan State University
Flint, Michigan, United States - (and 2 more...)
|
| 7 |
NCT03068923 |
Recruiting |
Thrombosis Outcomes in Pediatric Venous Thromboembolism |
|
|
Observational |
|
- University of Texas Southwestern Medical Center
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Postthrombotic syndrome (PTS)
- Symptomatic recurrent venous thromboembolism
- Post-pulmonary embolism (PE) impairment
- (and 2 more...)
|
200 |
All |
up to 21 Years (Child, Adult) |
NCT03068923 |
STU 122015-029
1K23HL132054-01 |
TOP |
May 2016 |
April 2020 |
April 2021 |
March 3, 2017 |
March 3, 2017 |
|
- Children's Medical Center
Dallas, Texas, United States
|
| 8 |
NCT02195232 |
Recruiting |
Cancer Associated Thrombosis and Isoquercetin (CAT IQ) |
- Thromboembolism of Vein VTE in Colorectal Cancer
- Thromboembolism of Vein in Pancreatic Cancer
- Thromboembolism of Vein in Non-small Cell Lung Cancer
|
|
Interventional |
Phase 2
Phase 3 |
- Dana-Farber Cancer Institute
- Quercegen Pharmaceuticals
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with Reduced D-dimer values
- Safety
- Cumulative Incidence of VTE at 56 days
|
618 |
All |
18 Years and older (Adult, Senior) |
NCT02195232 |
14-114 |
CAT IQ |
January 2015 |
August 2018 |
April 2023 |
July 21, 2014 |
February 6, 2018 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - VA Northern California Health Care System
Sacramento, California, United States - VA Connecticut Healthcare System
West Haven, Connecticut, United States - (and 8 more...)
|
| 9 |
NCT03075761 |
Recruiting |
Physical Activity in Children at Risk of Post-thrombotic Syndrome (PACT) |
- Post Thrombotic Syndrome
- Deep Vein Thrombosis
|
- Device: Fitbit
- Behavioral: 30-minute education session
|
Interventional |
Not Applicable |
- University of Texas Southwestern Medical Center
- Texas Scottish Rite Hospital for Children
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Proportion of screened patients who meet eligibility criteria
- Proportion of eligible patients who provide consent
- Level of adherence in the FitBit arm
- (and 3 more...)
|
44 |
All |
7 Years to 21 Years (Child, Adult) |
NCT03075761 |
STU 022016-057
1K23HL132054-01 |
PACT |
December 2016 |
December 2018 |
December 2019 |
March 9, 2017 |
March 9, 2017 |
|
- Children's Medical Center
Dallas, Texas, United States
|
| 10 |
NCT01936948 |
Recruiting |
Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial. |
|
|
Interventional |
Not Applicable |
- White River Junction Veterans Affairs Medical Center
- Dartmouth College
- Boston Scientific Corporation
|
U.S. Fed / Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Delayed bleeding complications
- Overall complications
- Complete polyp resection
- (and 2 more...)
|
1020 |
All |
18 Years to 89 Years (Adult, Senior) |
NCT01936948 |
CPHS-23578 |
|
April 2013 |
December 2020 |
December 2021 |
September 6, 2013 |
March 3, 2017 |
|
- White River Junction VAMC
White River Junction, Vermont, United States
|
| 11 |
NCT02767232 |
Not yet recruiting |
Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial |
- Deep Vein Thrombosis
- Post-Thrombotic Syndrome
- Venous Thrombosis
|
- Drug: Recombinant tissue plasminogen activator (rt-PA)
- Drug: Standard Anticoagulation Therapy
|
Interventional |
Phase 3 |
- University of Colorado, Denver
- RTI International
- Mid America Heart Institute
- (and 2 more...)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Development of Post-Thrombotic Syndrome (PTS)
- Change in Quality of Life (PedsQL)
- Change in Quality of Life (Peds-VEINES)
- (and 4 more...)
|
270 |
All |
6 Years to 21 Years (Child, Adult) |
NCT02767232 |
14-0659
ML29463 |
PHLO |
July 2018 |
April 2023 |
June 2023 |
May 10, 2016 |
September 20, 2017 |
|
|
| 12 |
NCT02081638 |
Recruiting |
Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study |
|
- Drug: Aspirin 81 mg daily
- Drug: Atorvastatin 40 mg daily
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- The primary end point will be change of sCD14 from Month 3 to Month 12 in the two groups combined (EC and ART <50).
- Changes in soluble biomarkers (sCD14, IL-6, D-dimer, hsCRP, sCD163, sTF as well as other relevant markers of inflammation and coagulation) in EC and ART <50 groups treated with ASA or ATV, independently within each group and arm and with grou...
- Changes in T cell activation (measured by HLA-DR/CD38 co- expression), monocyte immune activation (measured by activated monocyte subsets expressing either CD14++CD16+ and CD14varCD16+ and markers of activation, CCR5 and TF, and migration, CCR2 ...
- Changes in MR imaging of carotids after 9 months of statin or ASA in each group and both groups combined.
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT02081638 |
140039
14-I-0039 |
|
March 5, 2014 |
November 30, 2019 |
November 30, 2019 |
March 7, 2014 |
April 6, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - Hennipen County Medical Center
Minneapolis, Minnesota, United States
|
| 13 |
NCT03394755 |
Recruiting |
Thrombosomes® in Bleeding Thrombocytopenic Patients |
- Thrombocytopenia
- Hematologic Diseases
- Bone Marrow Aplasia
|
|
Interventional |
Phase 1 |
- Cellphire, Inc.
- Department of Health and Human Services
|
Industry / U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency of adverse events
- Changes in WHO Bleeding Grade
- Changes in Coagulation Measures
|
24 |
All |
18 Years to 68 Years (Adult, Senior) |
NCT03394755 |
2017-1 |
|
January 2018 |
September 18, 2018 |
December 18, 2018 |
January 9, 2018 |
January 24, 2018 |
|
- Hoxworth Blood Center
Cincinnati, Ohio, United States
|
| 14 |
NCT01638481 |
Recruiting |
Chronology of Occult and Gross Coagulopathy in Burn Patients |
|
|
Observational |
|
- Medstar Health Research Institute
- United States Department of Defense
|
Other / U.S. Fed |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
85 |
All |
18 Years and older (Adult, Senior) |
NCT01638481 |
58802-LS |
|
July 2012 |
December 2016 |
June 2017 |
July 11, 2012 |
July 14, 2016 |
|
- MedStar Washington Hospital Center
Washington, District of Columbia, United States
|
| 15 |
NCT02106429 |
Recruiting |
Platelet Activity in Vascular Surgery and Cardiovascular Events |
- Cardiovascular Disease
- Peripheral Artery Disease
- Critical Limb Ischemia
|
|
Observational |
|
- New York University School of Medicine
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Platelet activity measurements associated with short-term cardiovascular events in PAD patients
- Association between platelet activity measurements and long-term cardiovascular events in patients with established PAD
|
385 |
All |
21 Years and older (Adult, Senior) |
NCT02106429 |
14-00531
R01HL114978 |
PACE |
March 2014 |
January 2019 |
January 2019 |
April 8, 2014 |
November 20, 2017 |
|
- NYU Langone Medical Center and School of Medicine
New York, New York, United States
|
| 16 |
NCT03049475 |
Recruiting |
Pathophysiology of Acute Pain in Patients With Sickle Cell Disease |
|
|
Observational |
|
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- To measure and compare defined sets of markers of obstruction ofblood vessels (vaso-occlusion), red cell breakdown (hemolysis), and inflammation during acute painful crisis vs steady state in patients withsickle cell disease.
|
100 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03049475 |
170056
17-H-0056 |
|
March 13, 2017 |
October 31, 2021 |
October 31, 2021 |
February 10, 2017 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 17 |
NCT01554514 |
Recruiting |
Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura |
- Thrombotic Thrombocytopenic Purpura
|
|
Interventional |
Phase 2 |
- J. Evan Sadler, M.D., Ph.D.
- National Heart, Lung, and Blood Institute (NHLBI)
- Washington University School of Medicine
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of the composite primary outcome of exacerbation or refractory TTP
- Incidence of Durable Treatment Response
- Number of days to Durable Treatment Response
- (and 4 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT01554514 |
LDrituximab
1U54HL112303-01 |
|
August 2012 |
December 2018 |
December 2019 |
March 15, 2012 |
February 23, 2018 |
|
- Emory University
Atlanta, Georgia, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Washington University
Saint Louis, Missouri, United States - Duke University Medical Center
Durham, North Carolina, United States
|
| 18 |
NCT02776566 |
Recruiting |
Patient-Centered Anticoagulation Self-Monitoring in Minority Patients |
- Thromboembolism
- Blood Coagulation Disorders
- Cardiovascular Disease
- Vascular Disease
|
- Other: Patient Self-Monitoring vs Anticoagulation Clinic
|
Interventional |
Not Applicable |
- University of Illinois at Chicago
- National Heart, Lung, and Blood Institute (NHLBI)
- Roche Pharma AG
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Percent time in therapeutic range (TTR)
- Treatment Related Quality of Life
- Anticoagulation Related Knowledge
- (and 3 more...)
|
80 |
All |
21 Years and older (Adult, Senior) |
NCT02776566 |
2015-1193
K23HL112908 |
|
January 2016 |
February 2017 |
February 2017 |
May 18, 2016 |
May 18, 2016 |
|
- University of Illinois at Chicago
Chicago, Illinois, United States
|
| 19 |
NCT02927249 |
Recruiting |
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy |
- Node Positive HER2 Negative Breast Cancer
|
- Other: Placebo
- Drug: Aspirin
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- United States Department of Defense
- Bayer
|
Other / NIH / U.S. Fed / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Invasive disease-free survival (iDFS)
- Overall survival (OS)
- Distant disease free survival (DDFS)
- (and 2 more...)
|
2936 |
All |
18 Years to 69 Years (Adult, Senior) |
NCT02927249 |
A011502
NCI-2016-00233
U10CA180821-01 |
|
December 2016 |
April 2021 |
|
October 7, 2016 |
April 9, 2018 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 1176 more...)
|
| 20 |
NCT02426229 |
Recruiting |
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma |
- Scleroderma
- Interstitial Lung Disease
|
- Drug: dabigatran etexilate
|
Interventional |
Phase 1 |
- Medical University of South Carolina
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Composite: Safety of dabigatran patients with scleroderma interstitial lung disease. (complete blood counts, comprehensive metabolic profile, and coagulation studies).
- Composite: Preliminary estimate of efficacy of dabigatran in scleroderma. (skin score and dermal fibroblast biology)
|
15 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02426229 |
1R21AR065089-01A1 |
|
February 2016 |
August 2017 |
August 2017 |
April 24, 2015 |
March 23, 2017 |
|
- Medical University of South Carolina
Charleston, South Carolina, United States
|
| 21 |
NCT03419325 |
Recruiting |
A Genomic Approach for Clopidogrel in Caribbean Hispanics |
- Cardiovascular Disease (CVD)
- Stroke
- Acute Coronary Syndrome
- (and 3 more...)
|
- Genetic: CYP2C19 test
- Diagnostic Test: P2RY12 assay
|
Interventional |
Not Applicable |
- University of Puerto Rico
- National Institute on Minority Health and Health Disparities (NIMHD)
- Icahn School of Medicine at Mount Sinai
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Major adverse cardiovascular events (MACE) reductions
- number of patients with treatment-related cardiovascular (CV) death
- number of patients with treatment-related stent thrombosis
- Bleeding
|
250 |
All |
21 Years and older (Adult, Senior) |
NCT03419325 |
A4070417
2U54MD007600-31 |
|
January 17, 2018 |
June 30, 2020 |
June 30, 2022 |
February 1, 2018 |
February 1, 2018 |
|
- University Hospital at Carolina
Carolina, Puerto Rico - Cardiovascular Hospital of Puerto Rico and the Caribbean
San Juan, Puerto Rico
|
| 22 |
NCT03065465 |
Recruiting |
Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage |
- Upper Gastrointestinal Hemorrhage
|
- Device: Over-the-scope hemoclipping device
- Other: Standard endoscopic treatment
|
Interventional |
Not Applicable |
- CURE Digestive Diseases Research Center
- University of California, Los Angeles
- VA Greater Los Angeles Healthcare System
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- The rebleeding rate of non-variceal focal UGI lesions
- Obliteration rates of underlying arterial blood flow (detected by Doppler endoscopic probe)
- Rates of surgery or IR, complications, cross-over to other endoscopic treatment and death
|
45 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT03065465 |
OVESCO |
|
November 2015 |
July 2019 |
July 2019 |
February 28, 2017 |
February 28, 2017 |
|
- VA Greater Los Angeles Healthcare System
Los Angeles, California, United States - University of California, Los Angeles
Los Angeles, California, United States
|
| 23 |
NCT02634918 |
Recruiting |
Ultrasonography in Hemophilic Joint Disease and Serum Markers |
- Hemophilia A
- Hemophilia B
- Hemarthroses
|
|
Observational |
|
- Northwell Health
- National Cancer Institute (NCI)
- University of California, San Diego
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To determine the prevalence rates of synovial and cartilage changes using USG-PDS:
- To determine whether the presence/absence of synovial and cartilage changes measured using USG-PDS are associated with any changes in biological surrogate marker levels.
|
30 |
Male |
6 Months to 18 Years (Child, Adult) |
NCT02634918 |
#15-145 |
|
January 2016 |
December 2018 |
June 2019 |
December 18, 2015 |
April 5, 2018 |
|
- Feinstein Institute of Medical Research Northwell Health
New Hyde Park, New York, United States
|
| 24 |
NCT03463239 |
Not yet recruiting |
Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora |
- Urologic Diseases
- Male Urogenital Diseases
- Penile Diseases
- (and 3 more...)
|
- Biological: Autologous tissue engineered corpora
|
Interventional |
Phase 1 |
- Wake Forest University Health Sciences
- United States Department of Defense
|
Other / U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Number of participants with graft thrombosis or grant failures
|
10 |
Male |
18 Years to 60 Years (Adult) |
NCT03463239 |
IRB00046975 |
|
July 2018 |
December 31, 2021 |
December 31, 2022 |
March 13, 2018 |
April 6, 2018 |
|
- Wake Forest Institute for Regenerative Medicine
Winston-Salem, North Carolina, United States
|
| 25 |
NCT00114647 |
Recruiting |
Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies |
- Blood Component Removal
- Human Immunodeficiency Virus
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Completion of apheresis procedure
|
3000 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT00114647 |
810164
81-I-0164 |
|
October 19, 1981 |
|
|
June 16, 2005 |
April 19, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 26 |
NCT03474432 |
Not yet recruiting
New |
SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI |
- Percutaneous Coronary Intervention
- Optical Coherence Tomography
- In-stent Coronary Artery Restenosis
|
- Device: Optical Coherence Tomography
|
Interventional |
Not Applicable |
- Jesse Brown VA Medical Center
|
U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Stent strut coverage in LM PCI
- 12-month stent strut coverage in LM PCI
- Late Acquired Stent Malapposition (LASM)
- Major Adverse Cardiac Event (MACE)
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT03474432 |
JBVA-MIV-001 |
SOLEMN |
April 15, 2018 |
December 2019 |
December 2019 |
March 22, 2018 |
March 22, 2018 |
|
- Birmingham VA Medical Center
Birmingham, Alabama, United States - Southern Arizona VA Health Care System
Tucson, Arizona, United States - VA Long Beach Healthcare
Long Beach, California, United States - (and 9 more...)
|
| 27 |
NCT03167450 |
Recruiting |
Examining the Knowledge, Attitudes, and Beliefs of Sickle Cell Disease Patients, Parents of Patients With Sickle Cell Disease, and Providers Towards the Integration of CRISPR in Clinical Care |
|
|
Observational |
|
- National Human Genome Research Institute (NHGRI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Family-Based
- Time Perspective: Cross-Sectional
|
- Focus group interviews related to attitudes, beliefs, and opinions of those with SCD, parents of those with SCD, and providers on the use of CRISPR Cas9 gene-editing.
- To assess the utility of an educational tool for improving understanding of CRISPR Cas9.
|
160 |
All |
18 Years and older (Adult, Senior) |
NCT03167450 |
999917081
17-HG-N081 |
|
April 25, 2018 |
June 30, 2019 |
June 30, 2019 |
May 30, 2017 |
April 20, 2018 |
|
- National Human Genome Research Institute (NHGRI)
Bethesda, Maryland, United States
|
| 28 |
NCT02659930 |
Recruiting |
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma |
|
- Drug: liposomal doxorubicin
- Drug: pomalidomide
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- safety/tolerability of dose combinations
- pharmacokinetics of combination therapy
|
54 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02659930 |
160047
16-C-0047 |
|
January 20, 2016 |
November 1, 2021 |
November 30, 2021 |
January 21, 2016 |
November 21, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 29 |
NCT00029445 |
Recruiting |
Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors |
- Human Immunodeficiency Virus
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Studies of HIV-specific immunity
- Cohort Natural History Study
|
400 |
All |
18 Years and older (Adult, Senior) |
NCT00029445 |
020086
02-I-0086 |
|
January 4, 2002 |
|
|
January 14, 2002 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 30 |
NCT00050752 |
Recruiting |
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer |
- Renal Tumor Histology
- Cutaneous Leiomyoma
- Kidney Cancer
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Determine genotype/phenotype correlations.
- Determine the incidence and characteristics of HLRCC associated fumarate hydratase gene mutations.
- Define the types and characteristics (including patterns of growth) of renal cancer associated with HLRCC.
- (and 2 more...)
|
800 |
All |
4 Years to 65 Years (Child, Adult) |
NCT00050752 |
030066
03-C-0066 |
|
December 17, 2002 |
|
|
December 18, 2002 |
October 6, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 31 |
NCT00977977 |
Recruiting |
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy |
- Nephrotic Syndrome
- Proteinuria
- Autoimmune Disease
- (and 2 more...)
|
- Drug: Rituximab Infusion
- Drug: Oral Cyclosporine
|
Interventional |
Phase 2 |
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of complete and partial remissions; duration of remissions
- Safety; percent reduction in proteinuria
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT00977977 |
090223
09-DK-0223 |
|
September 1, 2009 |
January 1, 2020 |
January 1, 2020 |
September 16, 2009 |
March 29, 2018 |
|
- National Naval Medical Center
Bethesda, Maryland, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 32 |
NCT02061605 |
Recruiting |
First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy |
- Benign Renal Tumors
- Malignant Renal Tumors
|
- Device: Laser Tissue Welding Device
|
Interventional |
Phase 1 |
- Laser Tissue Welding, Inc.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Operative Blood Loss
- Postoperative Blood Loss
- Secondary hemorrhage or hematoma (safety issue no. 1)
- (and 3 more...)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02061605 |
LTW-LPN-01
R44DK094619-02 |
LTW-KIDNEY |
June 2016 |
December 2017 |
June 2018 |
February 13, 2014 |
May 8, 2017 |
|
- St. Luke's Episcopal Hospital
Houston, Texas, United States
|
| 33 |
NCT03395119 |
Recruiting |
Efficacy of Fish Oil or Olive Oil Supplementation on the Health Effects of Ozone Exposure in Healthy Young Subjects |
- Healthy
- Dietary Supplement
|
- Drug: Ozone
- Dietary Supplement: Fish Oil
- Dietary Supplement: Olive Oil
|
Interventional |
Phase 1 |
- University of North Carolina, Chapel Hill
- Environmental Protection Agency (EPA)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Change in forced expired volume in the first second (FEV1) from air exposure (Day 1) to ozone exposure (Day 2)
- endothelial cell function 1 hour post-exposure
- endothelial cell function 18 hour post-exposure
- (and 12 more...)
|
60 |
All |
18 Years to 35 Years (Adult) |
NCT03395119 |
15-2960 |
OMEGOZ |
December 18, 2017 |
December 18, 2020 |
December 18, 2020 |
January 10, 2018 |
March 6, 2018 |
|
- U.S. Environmental Protection Agency Human Studies Facility
Chapel Hill, North Carolina, United States
|
| 34 |
NCT02881554 |
Recruiting |
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery |
- Hepatocellular Carcinoma
- Intrahepatic Cholangiocarcinoma
- Stage IV Liver Cancer
- (and 3 more...)
|
- Procedure: Computed Tomography
- Procedure: Single Photon Emission Computed Tomography
- Drug: Technetium Tc-99m Sulfur Colloid
|
Interventional |
Not Applicable |
- University of Washington
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Changes in sulfur colloid uptake in single photon emission computed tomography/computed tomography imaging
- Sulfur colloid (SC) uptake on single photon emission computed tomography/computed tomography (SPECT/CT) imaging
|
60 |
All |
19 Years and older (Adult, Senior) |
NCT02881554 |
9646
NCI-2016-01198
P30CA015704 |
|
December 21, 2016 |
June 1, 2022 |
|
August 29, 2016 |
July 2, 2017 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States - ProCure Proton Therapy Center-Seattle
Seattle, Washington, United States
|
| 35 |
NCT02394730 |
Recruiting |
Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints |
|
- Drug: vorapaxar
- Drug: Placebo
|
Interventional |
Phase 1
Phase 2 |
- Kirby Institute
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Minnesota - Clinical and Translational Science Institute
- (and 2 more...)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Differences between treatment groups in mean change from baseline log10- d-dimer
- Proportion of participants in each treatment group with plasma HIV-1 RNA <50 copies/mL
- Differences between treatment groups in mean change from baseline in CD4+ cell counts
- (and 10 more...)
|
60 |
All |
40 Years and older (Adult, Senior) |
NCT02394730 |
2014-01-ADV
2013 bench to bedside grant |
ADVICE |
September 2015 |
December 2017 |
December 2017 |
March 20, 2015 |
June 22, 2017 |
|
- Georgetown University Hospital
Georgetown, Maryland, United States - Hennepin County Medical Centre
Minneapolis, Minnesota, United States - St Vincent's Hospital
Darlinghurst, New South Wales, Australia - (and 5 more...)
|
| 36 |
NCT03147768 |
Recruiting |
Laser Tissue Welding - Distal Pancreatectomy Sealing Study |
- Pancreatic Tumor, Benign
- Pancreatic Neoplasms
- Pancreatic Adenocarcinoma
- (and 11 more...)
|
- Device: Distal Pancreatectomy Sealing Using LTW
|
Interventional |
Phase 1 |
- Laser Tissue Welding, Inc.
- National Cancer Institute (NCI)
- CHI St. Luke's Health, Texas
|
Industry / NIH / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- PRIMARY EFFICACY AS A SEALANT: Intra-operative blood loss
- SECONDARY SAFETY: Post-operative blood loss requiring return to the operating room
- SECONDARY SAFETY: Prolonged post-operative pancreatic leakage
- SECONDARY SAFETY: Surgical space abscess
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT03147768 |
Phase I - LTW Pancreas Sealing
R44CA203052 |
LTW |
May 15, 2017 |
March 2019 |
June 2019 |
May 10, 2017 |
May 11, 2017 |
|
- Baylor CHI St. Luke's Medical Center
Houston, Texas, United States
|
| 37 |
NCT03473288 |
Not yet recruiting
New |
Rejuvenation of Aged Muscle Stem Cells Through Exercise |
- Autophagy and Apoptosis in Human Satellite Cells
|
- Behavioral: Exercise
- Behavioral: Sedentary
|
Interventional |
Not Applicable |
- Duke University
- National Institutes of Health (NIH)
- National Institute on Aging (NIA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Change in Muscle Stem Cell Function by Age Group
|
80 |
All |
21 Years and older (Adult, Senior) |
NCT03473288 |
Pro00084763
1K01AG056664 |
|
January 2, 2019 |
January 2, 2023 |
January 2, 2023 |
March 22, 2018 |
March 22, 2018 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
| 38 |
NCT02637427 |
Recruiting |
Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures |
- Blood Coagulation Disorders
- Hemorrhage
|
- Biological: Fresh frozen plasma transfusion
|
Interventional |
Phase 3 |
- Rutgers, The State University of New Jersey
- University of Pittsburgh
- Johns Hopkins University
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Hemoglobin Level
- Trial Feasibility (Rates of eligible and enrolled study subjects)
- Red Blood Cell Transfusion
- (and 9 more...)
|
110 |
All |
21 Years and older (Adult, Senior) |
NCT02637427 |
Pro20150001801
1R34HL125804-01A1 |
|
January 2016 |
April 2019 |
May 2019 |
December 22, 2015 |
May 23, 2017 |
|
- Johns Hopkins University, The Johns Hopkins Hospital
Baltimore, Maryland, United States - Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States
|
| 39 |
NCT02250534 |
Recruiting |
Project 1, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Childbearing Age Women |
|
- Other: Very low nicotine content cigarettes
|
Interventional |
Phase 1
Phase 2 |
- University of Vermont
- National Institute on Drug Abuse (NIDA)
- Johns Hopkins University
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
|
282 |
Female |
18 Years to 44 Years (Adult) |
NCT02250534 |
P50DA036114:P1S2
P50DA036114 |
|
October 2016 |
October 2019 |
October 2019 |
September 26, 2014 |
October 6, 2016 |
|
- Johns Hopkins University
Baltimore, Maryland, United States - University of Vermont
Burlington, Vermont, United States
|
| 40 |
NCT02880176 |
Recruiting |
Steps to Eliminate Postoperative Problems |
|
- Other: Financial Incentive to Increase Ambulation
|
Interventional |
Not Applicable |
- University of Pennsylvania
- Children's Hospital of Philadelphia
- National Center for Advancing Translational Science (NCATS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of Days Step Goal Completed
- Number of steps taken per day
- Composite morbidity outcome of complications, unplanned readmissions, or Emergency Department visits
- Functional Decline as assessed by the Stanford Health Assessment Questionnaire (SHAQ)
|
46 |
All |
21 Years and older (Adult, Senior) |
NCT02880176 |
825215
UL1TR000003 |
STEPP |
August 2016 |
May 2018 |
June 2018 |
August 26, 2016 |
June 16, 2017 |
|
- Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 41 |
NCT02345356 |
Recruiting |
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics |
- Atrial Fibrillation
- Deep Vein Thrombosis
- Cardiac Valvular Insufficiency
- (and 2 more...)
|
- Genetic: Genotype-guided
- Other: Standard-of-Care
|
Observational |
|
- University of Puerto Rico
- National Institute on Minority Health and Health Disparities (NIMHD)
- Genomas, Inc
|
Other / NIH / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- time spent within therapeutic range
- number of warfarin dose adjustments
- time to stable anticoagulation
- events-free time
|
300 |
All |
21 Years to 90 Years (Adult, Senior) |
NCT02345356 |
A4070215
8G12MD007600 |
|
January 2016 |
July 2019 |
July 2019 |
January 26, 2015 |
January 23, 2018 |
|
- Miami VA Healthcare System
Miami, Florida, United States - UPR University Hospital at Carolina
Carolina, Puerto Rico - UDH University Hospital at Centro Medico
San Juan, Puerto Rico
|
| 42 |
NCT01431326 |
Recruiting |
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care |
- Adenovirus
- Anesthesia
- Anxiety
- (and 47 more...)
|
- Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
|
Observational |
|
- Daniel Benjamin
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- The EMMES Corporation
- Duke University
|
Other / NIH / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Composite of pharmacokinetic outcomes for understudied drugs in children
- Composite pharmacodynamic outcomes of understudied drugs in children
- Biomarkers associated with understudied drugs in children
|
10000 |
All |
up to 21 Years (Child, Adult) |
NCT01431326 |
Pro00029638
IND 113645
IND 114369
IND 114531
IND 118358
HHSN20100006
HHSN27500020
HHSN27500027
HHSN27500043
HHSN27500049 |
PTN_POPS |
November 2011 |
February 2020 |
February 2020 |
September 9, 2011 |
April 4, 2018 |
|
- Alaska Native Medical Center
Anchorage, Alaska, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - University of California at San Diego Medical Center
La Jolla, California, United States - (and 51 more...)
|
| 43 |
NCT01742117 |
Recruiting |
Tailored Antiplatelet Therapy Following PCI |
- Coronary Artery Disease
- Acute Coronary Syndrome
- Stenosis
|
- Drug: Clopidogrel
- Drug: Ticagrelor
- Genetic: Retrospective Genotype testing
- Genetic: Prospective Genotype testing
|
Interventional |
Phase 4 |
- Mayo Clinic
- Spartan Bioscience Inc.
- Applied Health Research Centre
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / Industry / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of the a major adverse cardiovascular event (MACE)
- Number of subjects with reduced function CYP2C19 allele(s) who have major or minor bleeding
|
5270 |
All |
18 Years and older (Adult, Senior) |
NCT01742117 |
11-006837
5U01HL128606 |
TAILOR-PCI |
May 2013 |
September 2019 |
March 2020 |
December 5, 2012 |
November 21, 2017 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Sharp HealthCare
San Diego, California, United States - Zuckerberg San Francisco General
San Francisco, California, United States - (and 37 more...)
|
| 44 |
NCT02930226 |
Recruiting |
Ascending Doses of Autologous FDP vs FFP |
- Freeze Dried Plasma in Healthy Volunteers
|
- Biological: Autologous Freeze Dried Plasma (FDP)
- Biological: Fresh Frozen Plasma (FFP)
|
Interventional |
Phase 1 |
- U.S. Army Medical Research and Materiel Command
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Safety of single infusions of FDP at increasing fixed doses in normal healthy subjects by evaluating vital signs and laboratory tests
- Safety of fixed-dose infusions of 3 FDP units in comparison to 3 FFP units in normal healthy subjects by evaluating vital signs and laboratory tests
- Document if changes in specific coagulation values are within clinically meaningful levels pre and post infusion by evaluating laboratory tests
- (and 2 more...)
|
24 |
All |
18 Years to 55 Years (Adult) |
NCT02930226 |
S-14-12
IND 17154 |
FDP |
May 1, 2016 |
June 2018 |
December 2018 |
October 12, 2016 |
January 16, 2018 |
|
- Hoxworth Blood Center
Cincinnati, Ohio, United States
|
| 45 |
NCT03317405 |
Not yet recruiting |
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery |
- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- Ductal Breast Carcinoma In Situ
- (and 13 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Other: Placebo
- (and 2 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Incidence of skin toxicity
- Drug concentration
- Breast tissue biomarkers
- (and 3 more...)
|
38 |
Female |
18 Years and older (Adult, Senior) |
NCT03317405 |
NCI-2017-01921
N01-CN-2012-00035
NCI2017-09-01
NWU2017-09-01
N01CN00035
P30CA060553 |
|
May 1, 2018 |
March 1, 2019 |
September 1, 2019 |
October 23, 2017 |
April 18, 2018 |
|
- Cedars Sinai Medical Center
Los Angeles, California, United States - Northwestern University
Chicago, Illinois, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 46 |
NCT02348515 |
Recruiting |
Cardiovascular Disease Protection Tissue |
|
- Procedure: Heart failure or coronary disease
- Procedure: Heart transplant patients
- Procedure: Orthotopic Heart Transplant Patients
- (and 2 more...)
|
Observational |
|
- University of Florida
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Imbalance of vasoprotective and vasodeleterious axes of the renin angiotensin system (RAS) is associated with dysfunction of CPC isolated from diseased tissue
- Screening for biomarkers related to clinic outcome in the blood
|
180 |
All |
18 Years and older (Adult, Senior) |
NCT02348515 |
201300122-N
R01HL056921 |
|
June 2013 |
May 2018 |
October 2018 |
January 28, 2015 |
April 5, 2018 |
|
- Yanfei Qi
Gainesville, Florida, United States
|
| 47 |
NCT02412982 |
Recruiting |
Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients |
- Traumatic Injury
- Venous Thromboembolism
|
- Drug: Enoxaparin 40 mg q12h
- Drug: Enoxaparin 30 mg q8h
|
Interventional |
Phase 4 |
- University of Cincinnati
- United States Air Force
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Initial AT-III activity -- control group vs. other two groups combined
- Goal anti-Xa attainment / first repeat assessment
|
200 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02412982 |
Droege2015 |
|
March 2016 |
May 2018 |
July 2018 |
April 9, 2015 |
October 25, 2017 |
|
- University of Cincinnati Medical Center
Cincinnati, Ohio, United States
|
| 48 |
NCT02135419 |
Recruiting |
Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions |
- Anal Cancer
- High-grade Squamous Intraepithelial Lesion
- HIV Infection
- Human Papilloma Virus Infection
|
- Drug: imiquimod
- Drug: fluorouracil
- Device: infrared photocoagulation therapy
- (and 4 more...)
|
Interventional |
Phase 3 |
- AIDS Malignancy Consortium
- National Cancer Institute (NCI)
- The EMMES Corporation
- (and 2 more...)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Time to anal cancer
- Incidence of adverse events for each treatment
- Quality of life assessed using the Functional Assessment of Incontinence Therapy - Fecal (FAIT-F) questionnaire
|
5058 |
All |
35 Years and older (Adult, Senior) |
NCT02135419 |
AMC-A01
NCI-2014-00636
U01CA121947 |
ANCHOR |
September 24, 2014 |
June 30, 2022 |
June 30, 2022 |
May 12, 2014 |
March 23, 2018 |
|
- UCLA CARE Clinic
Los Angeles, California, United States - UCLA School of Nursing
Los Angeles, California, United States - University of California at San Francisco Anal Dysplasia Clinic
San Francisco, California, United States - (and 18 more...)
|
| 49 |
NCT01902381 |
Recruiting |
CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy |
- Previously Treated Myelodysplastic Syndromes
|
- Drug: 6,8-bis(benzylthio)octanoic acid
|
Interventional |
Phase 2 |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate (RR), defined as the combined rate of complete remission (CR), marrow CR, partial remission (PR), or stable disease (SD), as described by Cheson, et al. (2006)
- Safety profile of CPI-613, based on evaluation of symptoms, vital signs, ECOG performance status and survival, clinical chemistry, hematology, and coagulation, assessed by National Cancer Institute Common Terminology Criteria for Adverse Events v 4.0
- Progression-free survival (PFS)
- (and 3 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT01902381 |
CCCWFU 29113
NCI-2013-01312
P30CA012197 |
|
August 2013 |
August 2018 |
August 2018 |
July 18, 2013 |
November 20, 2017 |
|
- Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina, United States
|
| 50 |
NCT01811550 |
Recruiting |
Study of Procoagulation Markers in Stroke Patients |
- Stroke
- Hyperglycemia
- Procoagulation Markers
|
|
Observational |
|
- Temple University
- National Institute of Neurological Disorders and Stroke (NINDS)
- Neurological Emergencies Treatment Trials Network (NETT)
- (and 4 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- change in biomarker between patients with favorable versus unfavorable functional outcome
- Changes in biomarker levels between patients with versus without stroke recurrence at 90 days post stroke.
|
315 |
All |
18 Years and older (Adult, Senior) |
NCT01811550 |
11110979
1U01NS079077-01A1 |
I-SPOT |
August 2012 |
November 2019 |
November 2019 |
March 14, 2013 |
January 31, 2018 |
|
- Banner University Medical Center
Tucson, Arizona, United States - Long Beach Memorial Hospital
Long Beach, California, United States - Ronald Regan Medical Center
Los Angeles, California, United States - (and 37 more...)
|
Create an RSS feed from your search for:
Download the search results for: